BioAge Labs, Inc.

NASDAQ:BIOA

Biotechnology

Healthcare
$4.77 +2.35%

+$0.47 today

Market cap
$179.59M
Beta
0.95
P/E (TTM)
-9.7
EPS (TTM)
-$2.12
52W Low $4.07High $24.00

Volume 0.64M

Average 0.46M

BIOA Common Stock Issued

Cash raised by issuing new shares.

BioAge Labs, Inc.NASDAQ: BIOA

Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026

Common stock issued outflow grows to $126.02M

Q1 FY2026 common stock issued was $126.02M, compared with $0 a year earlier. Trailing-twelve-month common stock issued was $143.89M. Over 3 fiscal years it compounded at +640.5% a year.

Context

  • Common stock issued amounted to 198.7% of revenue in FY2025.
  • Common stock issued increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly common stock issued holds near $126.02M or moves back toward the trailing-twelve-month quarterly average of $35.97M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$126.02M+605.3% QoQ
Last fiscal yearDec 2025
$17.87M-91.9% YoY
LTMMar 2026
$143.89M+420.9% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-91.9%——
3-year CAGR+640.5%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
17.87M USD
Year-over-year change
-91.9%
3-year CAGR
+640.5%

Common Stock Issued vs competitors

How BIOA compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +420.9% is the 3rd highest of 9, against a peer median of +45.4%.
  • Common stock issued amounts to 1394.8% of revenue for BIOA, versus a peer median of 55.4%.
BIOA Competitors
Common Stock Issued for BIOA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGCCanopy Growth CorporationLTM Mar 2026CA$408.55M CAD+6.0%+609.2%130.8%
BIOABioAge Labs, Inc.LTM Mar 2026$143.89M USD+420.9%+640.5%1394.8%
CABACabaletta Bio, Inc.LTM Mar 2026$135.94M USD+1085.7%+48.0%—
HUMAHumacyte, Inc.LTM Mar 2026$92.94M USD+84.7%+496.3%4610.1%
EDITEditas Medicine, Inc.LTM Mar 2026$41.66M USD-27.3%+223.2%107.7%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$33.73M USD-72.5%+99.0%—
ACBAurora Cannabis Inc.LTM Mar 2026CA$9.94M CAD+1112.0%-48.6%3.2%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$945K USD+270.6%+4.0%—
TKNOAlpha Teknova, Inc.LTM Mar 2026$144K USD-99.1%-21.7%0.3%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$8K USD——0.0%
Peer median (excluding BIOA) —+45.4%+73.5%55.4%

Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(39.72M)(63.85M)(71.11M)(80.61M)
Depreciation & Amortization129K162K167K213K
Deferred Income Tax0000
Stock-Based Compensation2.54M3.02M6.98M11.69M
Change in Working Capital795K6.71M11.18M(11.83M)
Accounts Receivables000(769K)
Inventory0000
Accounts Payables994K(393K)6K788K
Other Working Capital(199K)7.1M11.17M(11.85M)
Other Non-Cash Items77K16.6M1.27M(1.1M)
Operating Cash Flow(36.18M)(37.36M)(51.52M)(81.63M)
Capital Expenditures(103K)(166K)(366K)(719K)
Acquisitions (Net)0000
Purchases of Investments0(100K)0(154.75M)
Sales of Investments00060.25M
Other Investing Activities0000
Investing Cash Flow(103K)(266K)(366K)(95.22M)
Debt Repayment2.5M35M(6M)(6M)
Common Stock Issued44K0221.62M17.87M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(45K)(59K)(4.42M)(400K)
Financing Cash Flow2.5M34.94M381.2M11.47M
Effect of Forex Changes246K081K(87K)
Net Change in Cash(33.54M)(2.69M)329.39M(165.46M)
Free Cash Flow(36.28M)(37.53M)(51.89M)(82.35M)

BioAge Labs, Inc.

NASDAQ:BIOA

Intrinsic Alpha fair value

Locked

Current Price

$4.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.